Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Parr Biotechnology (Hebei) Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution is currently limited to 1 distinct art unit and 1 distinct examiner. This focus suggests that the company's pending applications are concentrated within a specific technical niche at the patent office. Practitioners should consider the examination trends within this distinct art unit when preparing responses for the company.
ZOU, NIANXIANG serves as the busiest examiner with 1 busiest examiner pending action. This examiner is responsible for the company's current pending workload at the patent office. With 1 distinct examiner handling all pending matters, the company can maintain a consistent dialogue with the examiner. This arrangement simplifies the management of the company's pending prosecution in the Biotechnology & Pharmaceuticals sector by centralizing the review process under the assigned official.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZOU, NIANXIANG | 1 | 64.0% | +25.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557748 | APPLICATION OF ARTIFICIALLY SYNTHESIZED CPG SINGLE-STRANDED DEOXYOLIGONUCLEOTIDE IN VACCINES | ZOU, NIANXIANG | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557748 | APPLICATION OF ARTIFICIALLY SYNTHESIZED CPG SINGLE-STRANDED DEOXYOLIGONUCLEOTIDE IN VACCINES | ZOU, NIANXIANG | 1671 | §102§103§112DP | Final Rejection | — | Pending | Dec 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialParr Biotechnology (Hebei) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nianxiang Zou has the most, with 1 of Parr Biotechnology (Hebei) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
